FDA Brief

Warning letters Food

FDA warning letter to

Fertility Nutraceuticals LLC

High riskIssued May 20, 2021Posted May 26, 2021Center for Food Safety and Applied Nutrition

FDA and FTC told Fertility Nutraceuticals its three fertility supplements are unapproved drugs because of disease-treatment claims online and in shipping inserts.

What happened

FDA reviewed the company's two websites in March 2021 and found pages taking orders for CONFLAM-Forte, FERTINATAL DHEA and OVOENERGEN CoenzymeQ10, with claims that the products reduce miscarriage risk, improve IVF success and treat inflammatory and autoimmune conditions. FDA also cited a product insert and label shipped with CONFLAM-Forte that made similar disease-related claims. The Federal Trade Commission reviewed the same websites in May 2021 and questioned whether the advertising claims were backed by reliable scientific evidence.

What FDA found

  1. Website text and a shipped insert say the supplements prevent miscarriage, improve IVF success and treat conditions like autoimmune disease, which makes them drugs under the law.

    FD&C Act section 201(g)(1)(B) [21 U.S.C. § 321(g)(1)(B)]
  2. The products are not generally recognized as safe and effective for those uses, so they are unapproved new drugs being sold without FDA approval.

    FD&C Act sections 201(p), 505(a) [21 U.S.C. §§ 321(p), 355(a)]
  3. CONFLAM-Forte is meant for diseases a person cannot safely diagnose or treat alone, so no adequate directions for use can be written for it, and it is misbranded.

    FD&C Act section 502(f)(1) [21 U.S.C. § 352(f)(1)]
  4. Shipping a misbranded drug in interstate commerce is illegal.

    FD&C Act section 301(a) [21 U.S.C. § 331(a)]
  5. Shipping an unapproved new drug in interstate commerce is illegal.

    FD&C Act section 301(d) [21 U.S.C. § 331(d)]
  6. FTC says the disease-prevention and treatment advertising may not be backed by competent and reliable scientific evidence.

    FTC Act, 15 U.S.C. § 41 et seq.

What FDA wants

The company must write to FDA's Aaron Dotson within 15 working days describing the specific steps taken to fix the violations and prevent them from recurring, with supporting documents, or explain why it disagrees or needs more time. It must also notify the FTC's Richard Cleland within 15 working days of actions taken on the advertising claims.

Who should pay attention

  • dietary supplement brands making fertility or disease-related claims
  • marketers who cite third-party studies to support health claims
  • online sellers who ship product literature with orders

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk